Necrotizing Bacterial Dermohypodermitis-necrotizing Fasciitis Mono- or Multi-microbial Streptococcus Beta-haemolytic
France100 participantsStarted 2020-09-01
Plain-language summary
The aim of the study is to evaluate streptococcal carriage by swab, pharyngeal, anal and perineal in patients with DHBN-FN, in the entourage living under the same roof as well as patients with erysipelas
The main hypothesis is the major role of chronic porting of patients and entourage in DHBN-FN to SBH.
Indeed, the chronic pharyngeal / anal / perineal carriage could be a gateway following a transient bacteremia for a DHBN-FN.
The transmission of germs from the surrounding to the patient plays a major role:
At the gateway level in the case of exogenous DHBN-FN At the origin of chronic carriage in the case of endogenous DHBN-FN Transmission of germs from the patient to the surrounding area also plays an important role in increasing the risk of invasive SBH infections in the surrounding area.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient:
* Major patient hospitalized for a DHBN-FN or erysipelas (clinical diagnosis determined at the entrance).
* Signed informed consent.
Case contact
* person of major age living under the same roof as a patient who has had a DHBN-FN.
* Signed informed consent
Exclusion Criteria:
* Patient:
* Minor patient
* Immunosuppressed patient: active hematology, poorly controlled HIV, neutropenia (PNN \<1000 / mm3).
* Patient under guardianship or curatorship
* Patient deprived of liberty by judicial or administrative decision
* Patient not affiliated to a social security scheme and not a beneficiary of such a scheme
Case contact
* Minor person
* Person under tutorship or curatorship
* Person deprived of liberty by judicial or administrative decision
* Person not affiliated with a social security
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Rate of beta-hemolytic streptococcus in patients with DHBN-FN
Timeframe: Day 0
2
Rate of beta-hemolytic streptococcus in patients with DHBN-FN
Timeframe: 1 month after hospitalization discharge
3
Rate of beta-hemolytic streptococcus in patients with DHBN-FN